159 related articles for article (PubMed ID: 24853220)
21. Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas.
Carbone A; Gloghini A; Volpe R
Cancer; 1992 Dec; 70(11):2691-8. PubMed ID: 1330287
[TBL] [Abstract][Full Text] [Related]
22. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
23. Mantle cell lymphoma and diffuse large B-cell lymphoma of the testis: a unique case of composite non-Hodgkin lymphoma.
Andhavarapu S; Crozier JA; Jiang L; Sher T
Eur J Haematol; 2014 Dec; 93(6):537-42. PubMed ID: 24750331
[TBL] [Abstract][Full Text] [Related]
24. Vitamin D levels in patients with non-Hodgkin lymphoma/diffuse large B-cell lymphoma, chronic lymphocytic leukemia and multiple myeloma.
Graklanov V; Popov V
J Int Med Res; 2020 Jul; 48(7):300060520943421. PubMed ID: 32722995
[TBL] [Abstract][Full Text] [Related]
25. [Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms].
Xiao C; Su ZL; Wu QL; Gao HY; Fang JC; Xia ZJ; Guan ZZ
Zhonghua Bing Li Xue Za Zhi; 2005 Jan; 34(1):22-7. PubMed ID: 15796877
[TBL] [Abstract][Full Text] [Related]
26. Non-Hodgkin lymphoma of the Waldeyer's ring: clinicopathologic and therapeutic issues.
Laskar S; Mohindra P; Gupta S; Shet T; Muckaden MA
Leuk Lymphoma; 2008 Dec; 49(12):2263-71. PubMed ID: 19052973
[TBL] [Abstract][Full Text] [Related]
27. A systematic review of primary gastric diffuse large B-cell lymphoma: Clinical diagnosis, staging, treatment and prognostic factors.
Bai Z; Zhou Y
Leuk Res; 2021 Dec; 111():106716. PubMed ID: 34627052
[TBL] [Abstract][Full Text] [Related]
28. Extranodal non-Hodgkin's lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas.
Lal A; Bhurgri Y; Vaziri I; Rizvi NB; Sadaf A; Sartajuddin S; Islam M; Kumar P; Adil S; Kakepoto GN; Masood N; Khurshed M; Alidina A
Asian Pac J Cancer Prev; 2008; 9(3):453-8. PubMed ID: 19004134
[TBL] [Abstract][Full Text] [Related]
29. Non-Hodgkin's lymphoma involving the vagina: a clinicopathologic analysis of 14 patients.
Vang R; Medeiros LJ; Silva EG; Gershenson DM; Deavers M
Am J Surg Pathol; 2000 May; 24(5):719-25. PubMed ID: 10800991
[TBL] [Abstract][Full Text] [Related]
30. [Clinicopathological features and prognostic analysis of 151 patients with primary extra-nodal non-Hodgkin's lymphoma].
Wang C; Yuan C; He H; Bai O
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):858-62. PubMed ID: 25620485
[TBL] [Abstract][Full Text] [Related]
31. Clusterin expression in malignant lymphomas: a survey of 266 cases.
Saffer H; Wahed A; Rassidakis GZ; Medeiros LJ
Mod Pathol; 2002 Nov; 15(11):1221-6. PubMed ID: 12429802
[TBL] [Abstract][Full Text] [Related]
32. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
Kempf W
Semin Diagn Pathol; 2017 Jan; 34(1):22-35. PubMed ID: 27993440
[TBL] [Abstract][Full Text] [Related]
33. Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines.
Pedretti S; Urpis M; Leali C; Borghetti P; Baushi L; Sala R; Tucci A; Greco D; Pasinetti N; Triggiani L; Rossi G; Calzavara-Pinton P; Magrini SM; Buglione M
Tumori; 2018 Oct; 104(5):394-400. PubMed ID: 28218382
[TBL] [Abstract][Full Text] [Related]
34. Non-Hodgkin's lymphomas, version 4.2014.
Zelenetz AD; Gordon LI; Wierda WG; Abramson JS; Advani RH; Andreadis CB; Bartlett N; Byrd JC; Czuczman MS; Fayad LE; Fisher RI; Glenn MJ; Harris NL; Hoppe RT; Horwitz SM; Kelsey CR; Kim YH; Krivacic S; LaCasce AS; Nademanee A; Porcu P; Press O; Rabinovitch R; Reddy N; Reid E; Saad AA; Sokol L; Swinnen LJ; Tsien C; Vose JM; Yahalom J; Zafar N; Dwyer M; Sundar H;
J Natl Compr Canc Netw; 2014 Sep; 12(9):1282-303. PubMed ID: 25190696
[TBL] [Abstract][Full Text] [Related]
35. Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.
Kubuschok B; Trepel M
Expert Opin Drug Discov; 2017 Jul; 12(7):733-745. PubMed ID: 28494631
[TBL] [Abstract][Full Text] [Related]
36. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.
Kummer JA; Vermeer MH; Dukers D; Meijer CJ; Willemze R
J Invest Dermatol; 1997 Nov; 109(5):636-40. PubMed ID: 9347791
[TBL] [Abstract][Full Text] [Related]
37. B-cell lineage confers a favorable outcome among children and adolescents with large-cell lymphoma: a Pediatric Oncology Group study.
Hutchison RE; Berard CW; Shuster JJ; Link MP; Pick TE; Murphy SB
J Clin Oncol; 1995 Aug; 13(8):2023-32. PubMed ID: 7636544
[TBL] [Abstract][Full Text] [Related]
38. Immunological markers in non-Hodgkin's lymphomas.
Gobbi M; Mazza P; Mantovani W; Fiacchini M; Lauria F; Tura S
Boll Ist Sieroter Milan; 1979 Nov; 58(5):410-5. PubMed ID: 399843
[TBL] [Abstract][Full Text] [Related]
39. Non-Hodgkin's lymphomas presenting as cutaneous lesions.
Yaqoob N; Noorali S; Nasir MI; Pervez S
J Coll Physicians Surg Pak; 2003 Jan; 13(1):29-32. PubMed ID: 12685972
[TBL] [Abstract][Full Text] [Related]
40. The interrelationship between Hodgkin's disease and non-Hodgkin's lymphomas.
Jaffe ES; Zarate-Osorno A; Kingma DW; Raffeld M; Medeiros LJ
Ann Oncol; 1994; 5 Suppl 1():7-11. PubMed ID: 8172822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
